The effects of the IRA on our business and the healthcare industry in general is not yet known.
All entries for: Immune Diseases
August 5, 2026
Pfizer - New York
Layoffs
New York, NY
10,000+ employees
“Pfizer is adding $2.5 billion in cuts to an ongoing restructuring, with much of the new reduction coming from technology and simplification efforts across the New York pharma’s commercial, R&D and manufacturing functions.
The cuts under Pfizer’s Realigning Our Cost Base Program are expected to save $1 billion, the company announced Aug. 4 in its second-quarter earnings release. Most savings will occur between 2027 and 2029, but not for free: the program carries a one-time cost of $2 billion for digital enablement, implementation and severance.
A company spokesperson declined to give further details on how severance will be paid, whether any jobs will be affected, or what technological changes are planned.”
Disease Area: Antiviral, Cardiology, Dermatology, Gastrointestinal, Immune Diseases, Infectious Diseases, Metabolic Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
July 29, 2026
Biogen Inc
Neutral Outlook
Cambridge, MA
5,001-10,000 employees
Drug prices are under significant scrutiny in the markets in which our products are prescribed; for example the IRA has certain provisions related to drug pricing, including the ability for the U.S. government to set prices for certain drugs in Medicare. We expect drug pricing and other healthcare costs will continue to be subject to political and societal pressures on a global basis. As the policy environment remains dynamic, we will continue to monitor how uncertainty with respect to how the U.S. and foreign tariffs and the U.S. and international pricing may impact our business in the future.
Disease Area: Immune Diseases, Multiple, Neurological Diseases, Psychiatry, Rare Diseases
Drug Type: Biologic, Small Molecule
July 29, 2026
GSK/England
Layoffs
London, England
10,000+ employees
“GSK’s $2.5 billion restructuring over the next three years will include global job cuts, the company announced in a July 29 media call. CEO Luke Miels declined to say how many employees the U.K. pharma will let go, saying he wanted his team to discuss the changes with staff first and would provide an update once the plans are implemented. He framed the effort as a reallocation toward new medicines.
GSK intends to use part of the expected savings to keep funding its late-stage portfolio and pipeline. Some will also go toward improving margins and profitability ahead of the 2028 U.S. patent expiry for its HIV medicine dolutegravir.”
Disease Area: Antiviral, Immune Diseases, Multiple, Oncology, Respiratory Diseases
Drug Type: Biologic, Small Molecule
July 28, 2026
Incyte Corp
Neutral Outlook
Wilmington, DE
1,001-5,000 employees
In addition, the Inflation Reduction Act of 2022 (the “IRA”) introduced several significant changes to Medicare, including: requiring CMS to negotiate prices for certain high-expenditure, single source Medicare drugs; imposing inflation-based rebates on manufacturers whose prices increase faster than inflation; redesigning the Medicare Part D benefit to cap beneficiary out-of-pocket costs while requiring manufacturers to provide mandatory discounts under the Medicare Part D Manufacturer Discount Program beginning in 2025; and establishing penalties for manufacturers that fail to comply with applicable Medicare Drug Price Negotiation Program requirements.
Disease Area: Dermatology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
July 8, 2026
Novartis
Layoffs
Basel, Baselstadt
10,000+ employees
“In its largest layoff round this year, Novartis is cutting its East Hanover, New Jersey, workforce for a fourth time, letting go of 322 employees and bringing the site’s total to 572. The cuts take effect Oct. 2, per a WARN Act notice.
The first three rounds at the Swiss pharma’s East Hanover site were disclosed in March, April and May, affecting 114, 60 and 76 employees respectively. All are effective this year.
In total, Novartis has announced or disclosed at least 792 job cuts in 2026. In May, the company confirmed to BioSpace it was laying off a select number of staff in its biomedical research arm. That same month, it announced the closure of a production site in Wehr, Germany by the end of 2028, eliminating 220 jobs.”
Disease Area: Cardiology, Dermatology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
June 23, 2026
Tourmaline Bio
Layoffs
New York, NY
1-50 employees
Tourmaline Bio said goodbye to 60 employees at its New York headquarters months after being swallowed by Novartis.
The workforce reduction stems from the closure of a Tourmaline site at 27 West 24th in New York, according to a Workers Adjustment and Retraining Notification (WARN) alert for the state. The layoffs took effect May 29, though the notice was only posted last week.
Novartis moved to acquire Tourmaline in September last year, putting around $1.4 billion on the line on a fully diluted basis, the pharma said at the time. The transaction closed in late October.
Novartis has conducted several rounds of layoffs this year, including one that takes effect in August and will leave 76 New Jersey workers jobless. The pharma also announced in May that it would shutter a Germany facility by the end of 2028, which will affect 220 jobs. Novartis ran two other cycles of terminations—one in March and another in April—which together affected more than 170 staff in New Jersey.
Disease Area: Cardiology, Immune Diseases, Multiple
Drug Type: Biologic
June 12, 2026
Genentech
Layoffs
South San Francisco, CA
10,000+ employees
Genentech has made changes to its research and early development group (gRED) that include parting ways with a high-profile executive who had been with the company since 1997. The South San Franciso–based biotech confirmed to BioSpace the “targeted adjustments” and departure of Vishva Dixit, who most recently served as vice president and senior fellow, physiological chemistry, research biology.
The restructuring is intended to ensure the Roche subsidiary’s capabilities and investments align with its core therapeutic areas, advance its portfolio and deliver transformative medicines to patients faster, according to Genentech. A spokesperson declined to share specific information about the layoffs, including how many employees were affected.
Endpoints News reported that Genentech is closing infectious disease and physiological chemistry units while downsizing other teams. Also, in addition to Dixit, other key departures include Todd McDevitt, vice president and head of cell therapy, and Man-Wah Tan, a vice president and senior fellow of infectious diseases, the media outlet reported.
Disease Area: Dermatology, Immune Diseases, Infectious Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
May 27, 2026
Johnson & Johnson
Layoffs
New Brunswick, NJ
10,000+ employees
New Jersey’s job market is taking another hit, this time from pharma giant Johnson & Johnson, which is parting ways with 56 employees in New Brunswick, according to a Worker Adjustment and Retraining Notification (WARN) Act posting for the state. The layoffs will take effect on August 21.
This is J&J’s first announced workforce reduction of this year, according to a tally by BioSpace. But the pharma has for years been constantly reshaping its business to accommodate the loss of exclusivity of its autoimmune disease powerhouse Stelara—a campaign that has involved cutting back investments in other parts of its business, while putting more money into higher-value areas like cancer.
Other Big Pharma players to recently slash their New Jersey headcounts include Novartis, Bristol Myers Squibb and Novo Nordisk.
Disease Area: Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule